Clinical trials: Medium Vessel Occlusion
- Condition Medium Vessel Occlusion
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Atherosclerosis
A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis
The purpose of this study is to evaluate the effects of of rosuvastatin 20 mg compared to placebo for treating Chinese patients with subclinical atherosclerosis.
- Trial name
- NCT02546323
- Testing
- Rosuvastatin
- Where
- 24 sites in China
- Volunteers
- 543 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography
The purpose of this study is to demonstrate the (statistical) non-inferiority of iobitridol (Xenetix® 350) when compared to contrast agents with higher iodine concentrations, iopromide (Ultravist® 370) and iomeprol (Iomeron® 400)…
- Trial name
- X-ACT (NCT01255722)
- Testing
- iobitridol, iopromide, iomeprol
- Where
- 23 sites in France, Germany and 3 more
- Volunteers
- 468 people
- Sponsor
- Guerbet
Coronary Artery Disease, Coronary Heart Disease
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
The primary purpose of this study is to test the effect and safety of once daily ABT-335 on the thickness of the lining of the carotid artery (a blood vessel to the brain) in patients with abnormal blood lipids who have optimal…
- Conditions
- Coronary Artery Disease, Coronary Heart Disease, Dyslipidemia
- Trial name
- FIRST (NCT00616772)
- Testing
- ABT-335, Atorvastatin
- Where
- 124 sites in United States
- Volunteers
- 682 people
- Sponsor
- AbbVie (prior sponsor, Abbott)